Skip to content
lifestyle.hoteleguide.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Erasca, Inc.
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 15, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock
July 13, 2026
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
July 13, 2026
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
July 13, 2026
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 11, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 11, 2026
Erasca to Present at the Bank of America Securities Health Care Conference
May 6, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
March 12, 2026
1
2
Next Page
→